ArticleNature communications2018
Engineering yeast for the production of breviscapine by genomic analysis and synthetic biology approaches.
Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
91 citing papers in PubMed.
- Structural insights into a dual-substrate O-methyltransferase reveal the enzymatic mechanism of parallel paeonol biosynthesis.Nature communications · 2026Article
- Metabolic Engineering Strategies for Flavonoid Biosynthesis in Saccharomyces cerevisiae: Current Advances and Future Perspectives.Biotechnology and bioengineering · 2026Review
- EngineeredJournal of fungi (Basel, Switzerland) · 2026Article
- Protein design drives synthetic biology research of plant natural products.Biodesign research · 2025Review
- Synthetic biology for space exploration.NPJ microgravity · 2025Review
- Identification of genes involved in verazine biosynthesis in Veratrum grandiflorum and their heterologous production in Saccharomyces cerevisiae.BMC plant biology · 2025Article
- CYP98A monooxygenases: a key enzyme family in plant phenolic compound biosynthesis.Horticulture research · 2025Article
- Microscopy with microfluidics in microgravity using FlightScope.NPJ microgravity · 2025Article
- Diversity, Composition, and Ecological Function of Endophytic Fungal Communities Associated withMicroorganisms · 2025Article
- Molecular underpinnings ofPhysiology and molecular biology of plants : an international journal of functional plant biology · 2025Article
- Engineering scutellarin biosynthesis in Artemisia annua.Plant cell reports · 2025Article
- A long road ahead to reliable and complete medicinal plant genomes.Nature communications · 2025Review
- Engineering Saccharomyces cerevisiae for medical applications.Microbial cell factories · 2025Review
- Systematic metabolic engineering ofSynthetic and systems biotechnology · 2025Article
- Biochemical synthesis of taxanes from mevalonate.Synthetic and systems biotechnology · 2024Article
- Synthetic biology in plants.Plant biotechnology (Tokyo, Japan) · 2024Article
- Improvement and application of vacuum-infiltration system in tomato.Horticulture research · 2024Article
- P450Rdb: A manually curated database of reactions catalyzed by cytochrome P450 enzymes.Journal of advanced research · 2024Article
- Functional characterization, structural basis, and protein engineering of a rare flavonoid 2'-Acta pharmaceutica Sinica. B · 2024Article
- Advances in Engineering Nucleotide Sugar Metabolism for Natural Product Glycosylation inACS synthetic biology · 2024Review
31 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The flavonoid extract from Erigeron breviscapus, breviscapine, has increasingly been used to treat cardio- and cerebrovascular diseases in China for more than 30 years, and plant supply of E. breviscapus is becoming insufficient to satisfy the growing market demand. Here we report an alternative strategy for the supply of breviscapine by building a yeast cell factory using synthetic biology. We identify two key enzymes in the biosynthetic pathway (flavonoid-7-O-glucuronosyltransferase and flavone-6-hydroxylase) from E. breviscapus genome and engineer yeast to produce breviscapine from glucose. After metabolic engineering and optimization of fed-batch fermentation, scutellarin and apigenin-7-O-glucuronide, two major active ingredients of breviscapine, reach to 108 and 185 mg l
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.